Full-Time

Addictions Medicine Consult Team Nurse

AMCT

Updated on 9/3/2026

Deadline 6/10/27
Fraser Health

Fraser Health

10,001+ employees

Public health authority operating hospitals

Compensation Overview

CA$41.42 - CA$59.52/hr

Surrey, BC, Canada

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Medication Administration
Nursing

Get referred to Fraser Health

See people who can refer or advise you

Requirements
  • Current practicing registration as a Registered Nurse and/or Registered Psychiatric Nurse with the British Columbia College of Nurses and Midwives.
  • Eligibility for completion of the British Columbia Provincial Opiate Addiction Treatment Support Program course and approved related preceptorship.
  • Two years of recent related experience working with individuals with substance use disorders, or an equivalent combination of education, training and experience.
  • Demonstrated knowledge of substance use and harm reduction strategies, including assessment and intervention, current pharmacological approaches to substance use treatment, and treatment and recovery.
  • Demonstrated knowledge and skill in working with persons who use substances.
  • Knowledge of community, social, and mental health resources and services available for clients experiencing substance use challenges.
  • Comprehensive knowledge of nursing theory and practice within a patient- and family-centred model of care.
  • Ability to complete initial and ongoing client assessments and provide nursing care through appropriate or prescribed technical, therapeutic, and safety interventions, including crisis intervention.
  • Knowledge of counselling and group facilitation skills.
  • Ability to independently manage and prioritize caseload or workload and make decisions regarding care interventions.
  • Ability to promote person-centred care that demonstrates empathy for diverse populations, including individuals who use substances.
  • Demonstrated de-escalation and conflict-resolution skills.
  • Knowledge and skill in trauma-informed practice.
  • Demonstrated ability to model and mentor new staff and students.
  • Clinical proficiency in the designated clinical area.
  • Ability to communicate effectively both verbally and in writing.
  • Ability to work independently and collaborate with and promote cooperation among members of the interdisciplinary care team.
  • Ability to operate related equipment, including relevant computer applications.
  • Physical ability to perform the duties of the position.
Responsibilities
  • Perform substance use screening, physical and psychosocial assessments, and substance-use-focused pre-assessments for referrals to the Addictions Medicine Consult Team.
  • Develop, implement, evaluate, and modify individualized strength-based treatment and action plans in collaboration with clients, their families or natural supports, and the interdisciplinary team.
  • Provide individualized direct nursing care to designated clients and support direct-care staff using a harm-reduction lens, ensuring timely access to treatment and connecting or reconnecting clients to community care.
  • Initiate measures with the Addictions Medicine Consult Team to relieve crisis and emergent situations involving aggressive or suicidal behaviours, and share harm-reduction practices and relevant resources with staff.
  • Administer prescribed medicines and monitor clients’ medications, medication responses, and side effects; consult physicians regarding pharmaceutical needs.
  • Demonstrate and articulate the responsibilities of the authorized Registered Nurse or Registered Psychiatric Nurse prescriber to the interprofessional team and clients, and identify when client needs exceed the prescriber’s scope of practice.
  • Assess clients, understand their goals, and provide education and counselling related to substance use, harm reduction, relapse prevention, activities of daily living, medication use, side effects, and coping strategies.
  • Provide motivational interviewing to support clients across the continuum of care.
  • Initiate or participate in discharge planning, coordinate specialized services, and refer clients to community services and resources for substance use disorders and related comorbidities requiring urgent response and follow-up.
  • Coordinate cases, consult, provide recommendations, share relevant client information, discuss assessments, and provide clinical support to care teams while engaging stakeholders in treatment planning and evaluation.
  • Provide follow-up planning support.
  • Establish and enhance therapeutic relationships, promote self-care and informed decision-making, empower clients to improve quality of life, and advocate for and facilitate informed choices.
  • Document client, family, and natural-support perspectives, nursing assessments, and interventions; maintain complete and accurate records in accordance with procedures and policies.
  • Act as a preceptor or mentor to assigned new nursing staff and students, demonstrate care activities, provide guidance on clinical and health-related tasks, and participate in orientation.
  • Provide input to the Manager or designate regarding individual performance when requested.
  • Engage in team planning, development, evaluation, and quality-improvement activities, including team goal setting, problem solving, conflict resolution, and collaboration.
  • Attend meetings and in-services and provide input or recommendations regarding team policies, practices, and procedures to leadership.
  • Maintain professional development by reviewing relevant literature, attending educational workshops and in-services, keeping current with standards of practice, and consulting and networking with health-care professionals and community counsellors.
  • Participate in approved nursing and interdisciplinary research and projects by collecting data, summarizing information, and providing verbal updates for review and analysis.
  • Maintain a safe environment by adhering to safety and emergency practices, policies, and procedures, and report safety and risk concerns through the Patient Safety Learning System.
  • Perform other related duties as assigned.

Fraser Health is a health authority in British Columbia that provides a wide range of medical services to about 1.8 million people. It operates 12 hospitals, including major trauma centres, plus an outpatient care and surgery centre, and offers residential care, home health, public health, and mental health services. The organization employs over 40,000 staff, medical professionals, and volunteers who run clinics, care centres, and community programs. Its goal is to deliver accessible, high-quality care across the network while creating good workplaces for its employees and volunteers.

Company Size

10,001+

Company Stage

Grant

Total Funding

$20K

Headquarters

Surrey, Canada

Founded

2001

Get referred to Fraser Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The $18 million Mission Memorial ED expansion started construction in February 2026.
  • The Cloverdale UPCC opened January 28, 2026, with capacity for 64,000 annual visits.
  • Fraser Health won $1.3 million in March 2026 to expand Indigenous elder home care in Chilliwack.

What critics are saying

  • Mission Memorial ED faced repeated overnight shutdowns in May, June, and August 2026.
  • Physician staffing gaps still force service interruptions, signaling fragile emergency coverage across the network.
  • The Cloverdale hospital slipped from 2027 to 2030, weakening growth and credibility.

What makes Fraser Health unique

  • Fraser Health runs 12 hospitals and serves 1.8 million people across British Columbia.
  • Its Mission ED expansion adds 35% more space and reaches 41 care spaces by spring 2027.
  • Deloitte-backed AI scheduling models forecast patient surges and staffing demand across Fraser Health.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
StockTitan
Mar 24th, 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial.

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial. Rhea-AI Impact Rhea-AI Sentiment Rhea-AI summary. Arch Biopartners (OTCQB: ACHFF) announced a Clinical Trial Agreement with Fraser Health Authority to prepare Royal Columbian Hospital for recruitment in its Phase II trial of LSALT peptide for prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). Royal Columbian Hospital is now the ninth global site activated and the fourth Canadian recruiting site, after Toronto General Hospital, St. Michael's Hospital, and University of Calgary. Positive. * Royal Columbian Hospital received final Research Ethics Board and operational approvals * Royal Columbian Hospital became the 9th global site activated in the Phase II CS-AKI trial * 4 Canadian sites are actively recruiting patients (Toronto General, St. Michael's, Calgary, RCH) Negative. 03/24/2026 - 09:13 AM TORONTO, March 24, 2026 (GLOBE NEWSWIRE) - Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement ("CTA") with Arch to enable the Royal Columbian Hospital (RCH) to begin preparing for the recruitment phase in Arch's ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With the Clinical Trial Application (CTA) completed, RCH has now received final Research Ethics Board and operational approvals, including the final letter of authorization from Fraser Health. RCH will be the ninth site activated globally in the study and will be the fourth site to recruit patients in Canada. Toronto General Hospital, part of University Health Network, St. Michael's Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial. The Company is currently progressing feasibility and start-up discussions with additional leading cardiac surgery centres in Canada and the United States. About Arch Biopartners Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury. Arch's development pipeline includes: * LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI. * Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI. * CKD Platform: next-generation therapeutics targeting chronic kidney disease. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide[1]. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development. For more details about the Company's science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news. The Company has 66,933,289 common shares outstanding. | Aaron Benson Director of Communications Arch Biopartners, Inc. 647-428-7031 | / | | / | / | Send a message or subscribe for trial updates and company news at www.archbiopartners.com/contact-us Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company's future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in the Company's most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company's most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at www.sedarplus.ca. References: * Mark, Patrick B et al. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 2025;406(10518), 2461 - 2482. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01853-7/fulltext The scientific and medical content of this release has been reviewed and approved by the Company's Chief Science Officer. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Faq. What does the Clinical Trial Agreement with Fraser Health mean for Arch Biopartners (ACHFF)? It enables Royal Columbian Hospital to prepare for patient recruitment in the Phase II CS-AKI trial. According to the company, RCH now has final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health, supporting site activation. How many sites are active in Arch Biopartners' (ACHFF) Phase II LSALT CS-AKI trial after Royal Columbian Hospital activation? Royal Columbian Hospital is the ninth site activated globally in the study. According to the company, RCH is also the fourth site in Canada to reach activation and prepare for recruitment. Which Canadian hospitals are currently recruiting for Arch Biopartners' (ACHFF) Phase II CS-AKI trial? Toronto General Hospital, St. Michael's Hospital, University of Calgary, and now Royal Columbian Hospital are recruiting. According to the company, those four Canadian centres are actively enrolling new patients into the trial. What approvals did Royal Columbian Hospital receive to start recruitment for the ACHFF Phase II trial? RCH received final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health. According to the company, these approvals complete site readiness for recruitment and study start-up activities. Will Arch Biopartners (ACHFF) add more sites in Canada and the US for the Phase II CS-AKI trial? The company is progressing feasibility and start-up discussions with additional cardiac surgery centres in Canada and the United States. According to the company, those discussions aim to expand site activation beyond the current nine global sites.

Black Press Media
Mar 14th, 2026
$1.3M funding will help more Indigenous elders in Chilliwack with at-home care

$1.3M funding will help more Indigenous elders in Chilliwack with at-home care. Published 8:45 am Saturday, March 14, 2026 An at-home program that offers care to Indigenous elders in the Fraser Valley will be expanding, with the main focus on Chilliwack, thanks to $1.3 million in new funding. The Indigenous Caregiver Support Model (ICSM) is a home-based program that supports elders with "complex needs to age safely at home and in their community," according to a Fraser Health press release. It is one of five programs in B.C. benefitting from a total of $6.3 million in funding from Health Research BC over the next three years. The funding will advance research to help B.C. seniors age comfortably in their own home. The ICSM program was launched in 2023 as a pilot project and has supported 33 elders and their caregivers in the Eastern Fraser Valley, including Chilliwack. Its aim is to reduce caregiver strain and improve elder wellbeing by providing culturally safe, coordinated in-home support, training, and financial assistance for Indigenous families caring for elders. It is co-designed by Fraser Health Indigenous Health, Stó:lō Service Agency, First Nations Health Authority, and Métis Nation British Columbia. "This model is an example of what is possible when care is built on relationships, trust and community," said Amanda LaBoucane, interim vice president, Indigenous Health and Cultural Safety. "Many elders and caregivers in the Chilliwack area have experienced firsthand the impacts of residential schools and the child welfare system. By strengthening caregiver capacity and confidence while bridging into integrated clinical care teams run by and for Indigenous people, we see improved health and wellness and stronger relationships within and between communities." The program is currently operating in the Fraser Valley, including Chilliwack, but the expansion will focus on urban Chilliwack as that is an identified need, said Carrie Stefanson with Fraser Health. Caregivers receive skills training and an honorarium to help reduce the economic strain of caregiving, while elders receive regular home visits from Indigenous-led clinical teams who provide culturally safe, relationship-based care, rooted in trust, kindness and respect, according to a Fraser Health.

Fraser Health
Sep 12th, 2024
Leveraging artificial intelligence to assist with scheduling

Fraser Health has partnered with Deloitte Canada to develop and launch scheduling tools that leverage artificial intelligence (AI) and machine-learning solutions to accurately forecast the waves in demand Fraserhealth see in the health system.

Government of British Columbia
Aug 22nd, 2024
Permanent supportive, complex-care homes open in Fraser Valley

For people not already connected to services, Fraser Health will work in partnership with Coast Mental Health to provide on-site clinical supports, including services from a psychiatric nurse, community nurse, licensed practical nurse, social worker and traditional wellness practitioners.

Daily Hive
Sep 12th, 2023
Construction begins on Surrey's new $2.9 billion Cloverdale hospital

Through a procurement process, Fraser Health has selected Ellis-Don Design Build to design and build the new facility through a design-build agreement.